Inositol pyrophosphates, and methods of use thereof

Details Inositol pyrophosphates, and methods of use thereof Inositol pyrophosphates, and methods of use thereof

2006-01-09

2009-11-17

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C558S077000

Reexamination Certificate

active

07618954

ABSTRACT:
The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.

REFERENCES:
patent: 4192869 (1980-03-01), Nicolau et al.
patent: 4321259 (1982-03-01), Nicolau et al.
patent: 4404150 (1983-09-01), Tsunekawa et al.
patent: 4473496 (1984-09-01), Scannon
patent: 4478824 (1984-10-01), Franco et al.
patent: 4650786 (1987-03-01), Wong
patent: 4652449 (1987-03-01), Ropars et al.
patent: 4699926 (1987-10-01), Abraham et al.
patent: 4710488 (1987-12-01), Wong
patent: 4731381 (1988-03-01), Abraham et al.
patent: 4731473 (1988-03-01), Abraham et al.
patent: 4735936 (1988-04-01), Sirén
patent: 4751244 (1988-06-01), Abraham et al.
patent: 4752586 (1988-06-01), Ropars et al.
patent: 4777134 (1988-10-01), Siren
patent: 4794014 (1988-12-01), Siren
patent: 4797390 (1989-01-01), Siren
patent: 4826675 (1989-05-01), Gaffar et al.
patent: 4847082 (1989-07-01), Sabin
patent: 4851560 (1989-07-01), Siren
patent: 4873355 (1989-10-01), Hobbs et al.
patent: 4874690 (1989-10-01), Goodrich, Jr. et al.
patent: 4887995 (1989-12-01), Abraham et al.
patent: 4924023 (1990-05-01), Hobbs et al.
patent: 4931276 (1990-06-01), Franco et al.
patent: 4952717 (1990-08-01), Ozaki et al.
patent: 5003098 (1991-03-01), Siren et al.
patent: 5015634 (1991-05-01), Siren
patent: 5019566 (1991-05-01), Siren
patent: 5023248 (1991-06-01), Siren
patent: 5043261 (1991-08-01), Goodrich et al.
patent: 5051411 (1991-09-01), Siren
patent: 5057507 (1991-10-01), Siren
patent: 5082833 (1992-01-01), Shamsuddin
patent: 5091549 (1992-02-01), Ozaki et al.
patent: 5135923 (1992-08-01), Siren
patent: 5151539 (1992-09-01), Bright et al.
patent: 5210263 (1993-05-01), Kozikowski et al.
patent: 5252707 (1993-10-01), Ozaki et al.
patent: 5260287 (1993-11-01), Barreto et al.
patent: 5260472 (1993-11-01), Chen
patent: 5264605 (1993-11-01), Ozaki et al.
patent: 5274161 (1993-12-01), Siren et al.
patent: 5292913 (1994-03-01), Ozaki et al.
patent: 5295944 (1994-03-01), Teicher et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 5330979 (1994-07-01), Siren et al.
patent: 5344393 (1994-09-01), Roth et al.
patent: 5407924 (1995-04-01), Siren
patent: 5428007 (1995-06-01), Fischer et al.
patent: 5451205 (1995-09-01), Roth et al.
patent: 5545632 (1996-08-01), Siren
patent: 5612207 (1997-03-01), Nicolau et al.
patent: 5626884 (1997-05-01), Lockett
patent: 5720921 (1998-02-01), Meserol
patent: 5827837 (1998-10-01), Bevilacqua et al.
patent: 5846957 (1998-12-01), Siren
patent: 5866548 (1999-02-01), Tsien et al.
patent: 5866557 (1999-02-01), Persson et al.
patent: 5880099 (1999-03-01), Traynor-Kaplan et al.
patent: 5977078 (1999-11-01), Traynor-Kaplan et al.
patent: 6074605 (2000-06-01), Meserol et al.
patent: 6096916 (2000-08-01), Aneja
patent: 6187335 (2001-02-01), Brey et al.
patent: 6610702 (2003-08-01), Lehn et al.
patent: 7084115 (2006-08-01), Nicolau et al.
patent: 7084126 (2006-08-01), Frey, II et al.
patent: 2002/0028786 (2002-03-01), Frey, II et al.
patent: 2002/0142995 (2002-10-01), Nicolau et al.
patent: 2002/0173494 (2002-11-01), Lehn et al.
patent: 2003/0017150 (2003-01-01), Torphy
patent: 2003/0147937 (2003-08-01), Schwarz
patent: 2004/0014642 (2004-01-01), Nicolau et al.
patent: 2004/0147487 (2004-07-01), Traylor-Kaplan et al.
patent: 2005/0020542 (2005-01-01), Traynor-Kaplan et al.
patent: 2005/0227946 (2005-10-01), Siren
patent: 2005/0250743 (2005-11-01), Lehn et al.
patent: 2005/0272642 (2005-12-01), Frey, II et al.
patent: 2006/0009413 (2006-01-01), Frey, II et al.
patent: 2006/0014716 (2006-01-01), Frey, II et al.
patent: 2006/0030542 (2006-02-01), Frey, II et al.
patent: 0 392 697 (1990-10-01), None
patent: 0 508 488 (1992-10-01), None
patent: 52107239 (1977-09-01), None
patent: 1175989 (1989-07-01), None
patent: WO 87/05598 (1987-09-01), None
patent: WO 92/20369 (1992-11-01), None
patent: WO 94/21117 (1994-09-01), None
patent: WO 95/03068 (1995-02-01), None
patent: WO 95/05830 (1995-03-01), None
patent: WO 96/32136 (1996-10-01), None
patent: WO 01/13933 (2001-03-01), None
patent: WO 01/15738 (2001-03-01), None
patent: WO 01/24830 (2001-04-01), None
patent: WO 01/82932 (2001-11-01), None
patent: WO 02/10177 (2002-02-01), None
patent: WO 03/092700 (2003-11-01), None
Benesch et al., Intracellular Organic Phosphates as Regulators of Oxygen Release by Haemoglobin,Nature, vol. 221, pp. 618-622, Feb. 15, 1969.
Cosgrove, D.J., The Phosphorylation of epi-Inositol and muco-Inositol with Polyphosphoric Acid,Carbohydrate Research, vol. 40, pp. 380-384, Jan. 1, 1975.
Desai et al., The Preparation, Resolution, and Phosphorylation of Some Benzyl Ethers of myo-Inositol: Intermediates for the Synthesis of myo-Inositol Phosphates of the Phosphotidylinositol Cycle,Carbohydrate Research, vol. 225, pp. 209-228, Mar. 1, 1992.
Dinkel et al., Membrane-Permeant 3-OH-Phosphorylated Phosphoinositide Derivatives,Angewandte Chemie Intenational Edition, vol. 40(16), pp. 3004-3008, Aug. 17, 2001.
Lee et al., Synthesis of Mono and Unsymmetrical Bis Ortho Esters of scyllo-Inositol,Journal of Organic Chemistry, vol. 50, pp. 4402-4404, Jan. 1, 1985.
Lu et al., Molecular Interactions of Endogenous D-myo-Inositol Phosphates with the Intracellular D-myo-Inositol 1,4,5-Trisphosphate Recognition Site,Biochemistry, vol. 33, pp. 11586-11597, Jan. 1, 1994.
Menniti et al., Turnover of Inositol Polyphosphate Pyrophosphates in Pancreatoma Cells,The Journal of Biological Chemistry, vol. 68(6), pp. 3850-3856, Jan. 1, 1993.
Montchamp et al., Butane 2,3-Bisacetal Protection of Vicinal Diequatorial Diols,Journal of Organic Chemistry, vol. 61, pp. 3897-3899, Jan. 1, 1996.
Ruckpaul et al., “Interaction of Hemoglobin with Ions Allosteric Effects of the Binding of Anions”, Biochimica Et Biophysica Acta, vol. 236, 1971, pp. 211-221.
Nicolau et al., “Incorporation of Allosteric Effectors of Hemoglobin in Red Blood Cells. Physiological Effects”, Biblthca haemat., No. 51, 1985, pp. 92-107.
Teisseire et al., “Physiological Effects of High-P50Erythrocyte Transfusion on Piglets”, Journal of Applied Physiology, vol. 58, No. 6, Jun. 1985, pp. 1810-1817.
Teisseire et al., “Long-term Physiological Effects of Enhanced O2Release by Inositol Hexaphosphate-Loaded Erythrocytes”, Proceedings of the National Academy of Sciences, USA, vol. 84, No. 19, Oct. 1987, pp. 6894-6898.
Gersonde et al., “Modification of the Oxygen Affinity of Intracellular Haemoglobin by Incorporation of Polyphosphates into Intact Red Blood Cells and Enhanced O2Release in the Capillary System”, Biblthca haemat., No. 46, 1980, pp. 81-92.
Benesch et al., “The Effect of Organic Phosphates from the Human Erythrocyte on the Allosteric Properties of Hemoglobin”, Biochemical and Biophysical Research Communications, vol. 26, No. 2, 1967, pp. 162-167.
Arnone, Arthur, “X-ray Diffraction Study of Binding of 2,3-Diphosphoglycerate to Human Deoxyhaemoglobin”, Nature, vol. 237, May 19, 1972, pp. 146-149.
Gutman et al., Failure of Thalidomide to Inhibit Tumor Growth and Angiogenesis in Vivo,Anticancer Research, vol. 16, pp. 3673-3678, Jan. 1, 1996.
Hockel et al., Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects,Journal of the National Cancer Institute, vol. 93(4), pp. 266-276, Feb. 21, 2001.
Ishii et al., Decreased Medial Temporal Oxygen Metabolism in Alzheimer's Disease Shown by PET,The Journal of Nuclear Medicine, vol. 37(7), pp. 1159-1165, Jul. 1, 1996.
Thomas et al., Current Role of Thalidomide in Cancer Treatment,Current Opinions in Oncology, vol. 12, pp. 564-573, Jan. 1, 2000.
EntreMed Annual Report,Edgar Online, pp. 1-40, Mar. 3, 2000.
Adachi et al., Nucleation-Controlled Aggregation of Deoxyhemoglobins—Effect of Organic

Affiliated with

Also associated with

Rating

Inositol pyrophosphates, and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inositol pyrophosphates, and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inositol pyrophosphates, and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4088630